NuVasive positions itself as an innovator in spine surgery with a clinical evidence-based approach. As of Q2 2026 (May 2026), the company reported market capitalization of approximately $2.08 billion and demonstrated 8% year-over-year revenue growth in Q2. The company emphasizes reproducible surgical outcomes and patient-centered, minimally invasive solutions to address degenerative spinal conditions.
Cyborg Score Rationale
NuVasive shows solid profitability (6/10) and attractive valuation (9/10 per GuruFocus), with favorable market positioning in spine surgery. However, growth challenges (3/10) and competitive pressures in the medical device space moderate the score. Recent operational issues in Japan offset otherwise steady operational performance.
Top Insights
Q2 2026 (May) revenue of $741 million (+8% YoY), surpassing consensus estimates and driving annual guidance raise
Market capitalization ~$2.08B as of May 2026, with stock trading significantly below intrinsic value estimates (~27.7% undervalued per GuruFocus)
2025-2026 operational challenges: November 2025 Tokyo office raid and public apology; February 2026 news of photos of sales representatives inappropriately at medical facility
Full-year 2026 revenue projected at $1.57B (+6.23% vs. 2025), supported by U.S. cervical business robustness
Named Competitors
Globus Medical — Spine surgery and orthopedic devices
Orthofix — Orthopedic fixation systems and spinal solutions
Onkos Surgical — Minimally invasive spine surgery solutions